RTL therapy for multiple sclerosis: a Phase I clinical study. - Wikidata - wikimedia - TriplyDB

RTL therapy for multiple sclerosis: a Phase I clinical study.

RTL therapy for multiple sclerosis: a Phase I clinical study.

http://www.wikidata.org/entity/Q34520672

about

Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.Soluble MOG35-55/I-A(b) dimers ameliorate experimental autoimmune encephalomyelitis by reducing encephalitogenic T cells Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity.Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis Systemic immunotherapy delays photoreceptor cell loss and prevents vascular pathology in Royal College of Surgeons rats.Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion Effective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis.Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance Sex differences in the immune response to experimental stroke: Implications for translational research.Emerging immunopharmacological targets in multiple sclerosis.Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Partial MHC class II constructs as novel immunomodulatory therapy for stroke.MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics.Antigen-specific immunotherapies in rheumatic diseases.

P2860

Q34001070-8F149A25-79E3-4B94-9D0B-DD0F1F733463 Q34242088-A1E05395-D329-456A-8251-0124E92C3C40 Q34450848-C823B231-CD40-4C72-BBCB-5DA885F0AE75 Q35036755-DABE02FC-DE31-477F-972E-109C90B1F358 Q35234869-3A6A72ED-7AD6-4E88-AF6C-C504E6374A6C Q35637379-EC24A988-03F3-4AF6-BA5B-84210D06CCCC Q35722702-180742C2-33A8-45AD-AC86-73C0D732E768 Q35797272-7A7C8149-2B58-4C61-8E77-06CC59C2BD4C Q35893543-89A62638-6CC7-4134-97B3-0114D646ED81 Q35946934-83A602A8-4C15-4974-916C-C69C1BAB2A00 Q36231789-EA01C3E5-67A3-4AE2-8C9D-AC80DACF6E45 Q36790648-C80C2C85-27D6-4429-91F1-A2F1B5C59F44 Q37149410-5B5F0736-73B2-4FE8-89C1-CC725ED94F3B Q37210758-7F75929C-94E1-429A-8DF4-D88F96919A61 Q37212157-C8FDB324-6201-47A2-9120-0ADDD0729B26 Q37432327-BDD8A1CD-E57D-41F6-8485-839164A7D68E Q37559970-54314B7A-B73D-4D7A-AAFF-7E922BD326D7 Q38791052-55FA24F2-0A26-4CC8-A720-A120D5A6E3B4 Q38837294-18189100-E7AE-48D9-9C1B-D406E942B05B Q38988985-C99A455D-22E3-479D-8EBE-0C1CBDCEB474 Q39340752-065E8D4C-2633-48E2-8063-47E01939795B Q39431371-9CAE6A95-FFA8-41EF-9D8E-36338D8F80C5

P2860

RTL therapy for multiple sclerosis: a Phase I clinical study.

http://www.wikidata.org/entity/Q34520672

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

RTL therapy for multiple sclerosis: a Phase I clinical study.

@ast

RTL therapy for multiple sclerosis: a Phase I clinical study.

@en

RTL therapy for multiple sclerosis: a Phase I clinical study.

@nl

type

label

RTL therapy for multiple sclerosis: a Phase I clinical study.

@ast

RTL therapy for multiple sclerosis: a Phase I clinical study.

@en

RTL therapy for multiple sclerosis: a Phase I clinical study.

@nl

prefLabel

RTL therapy for multiple sclerosis: a Phase I clinical study.

@ast

RTL therapy for multiple sclerosis: a Phase I clinical study.

@en

RTL therapy for multiple sclerosis: a Phase I clinical study.

@nl

P1433

Q34520672-E9252D03-32F6-463F-A9FB-FA16190132CA

P1476

Q34520672-AAEE92D6-B4A1-4412-886F-960F1DF4E295

P2093

Q34520672-8CF10A4F-6C9F-42B5-9457-0F45E3E90B0C

Q34520672-AA9C11F7-2B7C-4617-9C98-D1B14CA4F07E

Q34520672-C3F22928-3732-4588-8B77-F2E102975848

Q34520672-D3A33A3D-3EBA-4746-84FE-60BC0FFD9FDE

P2860

Q34520672-0788B761-AA0D-4ED9-94E6-B420372592B5

Q34520672-0A516536-7855-420C-90F2-65BC986903F0

Q34520672-0C5CB3AE-749A-4F54-84E7-33FD726672C2

Q34520672-1BE398FC-04D7-4A05-9205-677D637FE307

Q34520672-33F68BA9-CD11-4EE0-97C6-F8217172283C

Q34520672-3FBD630C-72D7-4D53-B8BA-3A06B42D26F1

Q34520672-78F80A38-2ABF-4CA5-A178-69C95B8E91B1

Q34520672-91506B29-F6C7-4D04-8435-1BC5D548BC0E

Q34520672-93F7F56C-E046-4A33-8537-A89BEA4BC6FB

Q34520672-96FF6A59-0774-4A16-A461-90CB28DD653E

P304

Q34520672-63A899B5-9041-4DBF-A60B-B8BB44802474

P31

Q34520672-A7B01257-583A-495A-88F0-9D965312C442

P356

Q34520672-DA0D9834-0CC8-41E4-B0B8-AB06DC040ACE

P433

Q34520672-053782C5-8410-4EDA-96D2-5475B31972A0

P478

Q34520672-A5E157AF-AAC6-4601-AFB4-B72712F5DF2F

P50

Q34520672-35C442C6-E7B3-48D8-992D-919ACA9D8C6A

P577

Q34520672-C5CF2BEA-E71F-4ABF-9E15-9796EC0E59E2

P5875

Q34520672-C2E42729-B931-4F29-AFF9-E442AAF96815

P698

Q34520672-FFD1E118-84F9-4B82-91BC-87B361158962

P921

Q34520672-C0169127-A664-43C5-ABC2-81815927C96B

P932

Q34520672-B12DC497-0A0D-47B1-89E4-2EFE746AD493

P356

J.JNEUROIM.2010.09.013

P1433

Journal of Neuroimmunology

P1476

RTL therapy for multiple sclerosis: a Phase I clinical study

@en

P2093

Adolph J Ferro

http://www.w3.org/2001/XMLSchema#string

Arthur A Vandenbark

http://www.w3.org/2001/XMLSchema#string

Gregory G Burrows

http://www.w3.org/2001/XMLSchema#string

Halina Offner

http://www.w3.org/2001/XMLSchema#string

P2860

Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis

Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation.

Chemokines and glial cells: a complex network in the central nervous system.

Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease

Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand

Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis.

Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells.

Regulation of encephalitogenic T cells with recombinant TCR ligands.

P304

7-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JNEUROIM.2010.09.013

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

231

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47519367

http://www.w3.org/2001/XMLSchema#string

P698

20965577

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3026883

http://www.w3.org/2001/XMLSchema#string